4.3 Article

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Journal

JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 31, Issue 5, Pages 891-897

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2017.01.022

Keywords

Diabetes; Weight loss; Psychosocial; Diabetes distress; Commercial weight loss programs; Quality of life

Funding

  1. Weight Watchers International (WWI)

Ask authors/readers for more resources

Aims: Type 2 diabetes mellitus (T2DM) can substantially decrease quality of life (QOL). This study examined the effects on QOL-relevant psychosocial measures of a widely available commercial weight loss program enhanced for individuals with T2DM. Methods: A year-long multi-site randomized clinical trial compared the Weight Watchers (WW) approach, supplemented with phone and email counseling with a certified diabetes educator (CDE), to brief standard diabetes nutrition counseling and education (Standard Care; SC). Participants were 400 women and 163 men (N = 279 WW; 284 SC) with T2DM [mean ( +/- SD) HbA(1c) 8.32 +/- 1%; BMI = 37.1 +/- 5.7 kg/m(2); age = 55.1 +/- 9.1 years]. Psychosocial outcomes were assessed at baseline, month 6, and month 12 using a diabetes specific psychosocial measure (Diabetes Distress Scale [DDS]), Impact of Weight on Quality of Life-Lite scale (IWQOL), a generic QOL measure (SF-36), and a depression screen (PHQ-9). Results: WW participants showed significantly greater improvements than did SC participants on all DDS subscales and total score and on IWQOL total score and physical function, sex life and work domains (all ps < .05). There was no significant treatment effect on SF-36 scores or PHQ-9. Conclusions: WW enhanced for individuals with T2DM was superior to SC in improving psychosocial outcomes most specific to T2DM and obesity. Available commercial WL programs, combined with scalable complementary program-specific diabetes counseling, may have benefits that extend to diabetes-related distress and weight-relevant QOL. (C) 2017 The Authors. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Endocrinology & Metabolism

Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach

Michael R. Lewis, Robert C. Macauley, Patricia R. Sheehan, Myrlene A. Staten, Lawrence S. Phillips, Neda Rasouli, Anastassios G. Pittas

DIABETES CARE (2017)

Article Endocrinology & Metabolism

Randomized Controlled Trial of a Nationally Available Weight Control Program Tailored for Adults with Type 2 Diabetes

Patrick M. O'Neil, Karen Miller-Kovach, Peter W. Tuerk, Lynne E. Becker, Thomas A. Wadden, Ken Fujioka, Priscilla L. Hollander, Robert F. Kushner, W. Timothy Garvey, Domenica M. Rubino, Robert J. Malcolm, Daniel Weiss, William J. Raum, Jonny L. Salyer, Kathie L. Hermayer, Stephanie L. Rost, Jan L. Veliko, Nicoleta D. Sora

OBESITY (2016)

Article Endocrinology & Metabolism

Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers

Ken Fujioka, Patrick M. O'Neil, Melanie Davies, Frank Greenway, David C. W. Lau, Birgitte Claudius, Trine Vang Skjoth, Christine Bjorn Jensen, John P. H. Wilding

OBESITY (2016)

Article Medicine, General & Internal

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C. W. Lau, Luc Van Gaal, Rafael Violante Ortiz, John P. H. Wilding, Trine V. Skjoth, Linda Shapiro Manning, Xavier Pi-Sunyer

LANCET (2017)

Article Endocrinology & Metabolism

Characteristics of Weight Loss Trajectories in a Comprehensive Lifestyle Intervention

Ryan J. Marek, Sandra M. Coulon, Joshua D. Brown, Janet A. Lydecker, Scott Marek, Robert Malcolm, Patrick M. O'Neil

OBESITY (2017)

Article Endocrinology & Metabolism

Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study

Lee M. Kaplan, Angela Golden, Kimberly Jinnett, Ronette L. Kolotkin, Theodore K. Kyle, Michelle Look, Joseph Nadglowski, Patrick M. O'Neil, Thomas Parry, Kenneth J. Tomaszewski, Boris Stevenin, Soren Kruse Lilleore, Nikhil V. Dhurandhar

OBESITY (2018)

Article Endocrinology & Metabolism

Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts

Erin S. LeBlanc, Richard E. Pratley, Bess Dawson-Hughes, Myrlene A. Staten, Patricia R. Sheehan, Michael R. Lewis, Anne Peters, Sun H. Kim, Ranee Chatterjee, Vanita R. Aroda, Chhavi Chadha, Lisa M. Neff, Irwin G. Brodsky, Clifford Rosen, Cyrus V. Desouza, John P. Foreyt, Daniel S. Hsia, Karen C. Johnson, Philip Raskin, Sangeeta R. Kashyap, Patrick O'Neil, Lawrence S. Phillips, Neda Rasouli, Emilia P. Liao, David C. Robbins, Anastassios G. Pittas

DIABETES CARE (2018)

Article Medicine, General & Internal

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O'Neil, Andreas L. Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D. Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P. H. Wilding

LANCET (2018)

Editorial Material Medicine, General & Internal

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice COMMENT

Sean Wharton, Melanie Davies, Dror Dicker, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino, Sue D. Pedersen

Summary: GLP-1 receptor agonists are commonly used for treating type 2 diabetes and weight management, but gastrointestinal side effects can be a potential barrier to their use.

POSTGRADUATE MEDICINE (2022)

Article Endocrinology & Metabolism

A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity

Anders Strathe, Deborah B. B. Horn, Malte Selch Larsen, Domenica Rubino, Rasmus Sorrig, Marie Thi Dao Tran, Sean Wharton, Rune Viig Overgaard

Summary: This study aimed to determine the relationship between exposure to the GLP-1 analogue semaglutide and weight-loss trajectories for weight management. The researchers developed a population PK model and an exposure-response model based on data from various trials. The models accurately predicted 1-year weight loss and provided insight into the role of semaglutide in treating overweight and obesity.

DIABETES OBESITY & METABOLISM (2023)

Article Medicine, General & Internal

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

Patrick M. O'Neil, Domenica M. Rubino

Summary: Obesity negatively affects patients' health and quality of life, with various complications. Research shows that once-weekly subcutaneous semaglutide 2.4 mg can improve patients' quality of life, control of eating, and body composition. These findings emphasize the importance of semaglutide not only for weight loss but also for improving patients' wellbeing and daily activities.

POSTGRADUATE MEDICINE (2022)

Article Endocrinology & Metabolism

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

Patrick M. O'Neil, Vanita R. Aroda, Arne Astrup, Robert Kushner, David C. W. Lau, Thomas A. Wadden, Jason Brett, Ana-Paula Cancino, John P. H. Wilding

DIABETES OBESITY & METABOLISM (2017)

No Data Available